Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 25
- Profitability 5
- Business Quality 50
- Balance Sheet 35
- Cash Flow 60
Why this rating?
Health 32/100 — Avoid
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Taysha Gene Therapies, Inc. (TSHA) is a Biotechnology company in the Healthcare sector. Compound Radar rates Taysha Gene Therapies, Inc. 32/100 (Avoid) due to solid business quality and elevated leverage.
Investment profile
- Quality Moderate
- Balance Sheet Stretched
Financial highlights
Valuation
- Forward P/E -11.85
- EV/Revenue 259.98
Profitability
- Operating Margin -2792.3%
- Net Margin 0.0%
- ROE -47.1%
Financial strength
- Cash $455.41M
- Debt $56.71M
- Net Cash $398.69M
- Free Cash Flow $-93.83M
- Current Ratio 17.77
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Taysha Gene Therapies, Inc. (TSHA).